尽管取得了进展，但艾滋病防治之战远未结束：由于尚无治愈方法，专家敦促进行早期诊断并通过更好地坚持治疗进行及时治疗。
Despite Gains, the War on HIV Is Far From Over: With No Cure in Sight, Experts Urge Early Diagnosis and Prompt Treatment With Better Adherence.
作者信息
Worley Susan L
出版信息
P T. 2018 Jan;43(1):40-57.
Abstract
Although a significant increase in life expectancy for people with human immunodeficiency virus was reported last spring, experts in the U.S. caution that the results are not a cause for complacency. Efforts to develop a vaccine and a cure remain essential, as do efforts to develop interventions that may improve adherence.
摘要
尽管去年春天有报道称，感染人类免疫缺陷病毒的人群的预期寿命显著增加，但美国的专家们告诫说，这一结果并非可以让人高枕无忧。研发疫苗和治愈方法的努力仍然至关重要，研发可能提高依从性的干预措施的努力也同样重要。
相似文献
1
3
Measuring the impact of HIV/AIDS, heart disease and malignant neoplasms on life expectancy in the USA from 1987 to 2000.衡量1987年至2000年期间艾滋病毒/艾滋病、心脏病和恶性肿瘤对美国预期寿命的影响。
Public Health. 2006 Jun;120(6):486-92. doi: 10.1016/j.puhe.2005.12.009. Epub 2006 May 26.
4
Japan as the front-runner of super-aged societies: Perspectives from medicine and medical care in Japan.日本作为超老龄化社会的领跑者：来自日本医学与医疗护理的视角
Geriatr Gerontol Int. 2015 Jun;15(6):673-87. doi: 10.1111/ggi.12450. Epub 2015 Feb 5.
5
Improving treatment adherence in drug abusers who are HIV-positive.提高艾滋病毒呈阳性的药物滥用者的治疗依从性。
Lippincotts Case Manag. 2000 Nov-Dec;5(6):236-45; quiz 245-7. doi: 10.1097/00129234-200011000-00006.
6
Early HIV treatment led to life expectancy gains valued at $80 billion for people infected in 1996-2009.早期的 HIV 治疗使 1996-2009 年感染 HIV 的人群的预期寿命延长了 800 亿美元。
Health Aff (Millwood). 2014 Mar;33(3):370-7. doi: 10.1377/hlthaff.2013.0623.
7
Projecting the cost-effectiveness of adherence interventions in persons with human immunodeficiency virus infection.预测艾滋病病毒感染者依从性干预措施的成本效益。
Am J Med. 2003 Dec 1;115(8):632-41. doi: 10.1016/j.amjmed.2003.07.007.
8
Lifelong antiretroviral therapy or HIV cure: The benefits for the individual patient.终身抗逆转录病毒疗法或治愈艾滋病毒：对个体患者的益处。
AIDS Care. 2016;28(2):242-6. doi: 10.1080/09540121.2015.1074653. Epub 2015 Sep 11.
9
[Hurdles to HIV cure. Part 1 : the latent reservoirs].[实现艾滋病治愈的障碍。第1部分：潜伏病毒库]
Rev Med Liege. 2020 Sep;75(9):573-577.
10
Monkey Models and HIV Vaccine Research.猴模型与 HIV 疫苗研究。
Adv Exp Med Biol. 2018;1075:97-124. doi: 10.1007/978-981-13-0484-2_5.
引用本文的文献
1
Success rates and adherence to antiretroviral therapy among treatment-naïve patients in Davao City, Philippines: A ten-year retrospective cohort study.菲律宾达沃市初治患者抗逆转录病毒治疗的成功率和依从性：一项十年回顾性队列研究。
Dialogues Health. 2024 Sep 24;5:100195. doi: 10.1016/j.dialog.2024.100195. eCollection 2024 Dec.
2
Computational design and clinical demonstration of a copper nanocluster based universal immunosensor for sensitive diagnostics.基于铜纳米簇的通用免疫传感器用于灵敏诊断的计算设计与临床验证
Nanoscale Adv. 2019 Dec 3;2(1):304-314. doi: 10.1039/c9na00503j. eCollection 2020 Jan 22.
本文引用的文献
1
Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial.多替拉韦作为 HIV 的维持单药治疗（DOMONO）：一项 2 期、随机、非劣效性试验。
Lancet HIV. 2017 Dec;4(12):e547-e554. doi: 10.1016/S2352-3018(17)30152-2. Epub 2017 Oct 26.
2
Do Less Harm: Evaluating HIV Programmatic Alternatives in Response to Cutbacks in Foreign Aid.减少伤害：评估应对外国援助削减的艾滋病项目替代方案。
Ann Intern Med. 2017 Nov 7;167(9):618-629. doi: 10.7326/M17-1358. Epub 2017 Aug 29.
3
HIV-Associated Complications: A Systems-Based Approach.《HIV相关并发症：基于系统的方法》
Am Fam Physician. 2017 Aug 1;96(3):161-169.
4
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial.长效肌内注射卡替拉韦和利匹韦林治疗成人 HIV-1 感染（LATTE-2）：一项随机、开放标签、2b 期、非劣效性试验的 96 周结果。
Lancet. 2017 Sep 23;390(10101):1499-1510. doi: 10.1016/S0140-6736(17)31917-7. Epub 2017 Jul 24.
5
CROI 2017: Complications and Comorbidities of HIV Disease and Its Treatment.2017年逆转录病毒与机会性感染会议：HIV疾病及其治疗的并发症和合并症
Top Antivir Med. 2017 May/Jun;25(2):77-83.
6
U.S. HIV Incidence and Transmission Goals, 2020 and 2025.美国 2020 年和 2025 年艾滋病毒发病率和传播目标。
Am J Prev Med. 2017 Sep;53(3):275-281. doi: 10.1016/j.amepre.2017.03.012. Epub 2017 May 15.
7
Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies.1996 年至 2013 年开始抗逆转录病毒治疗的 HIV 阳性患者的生存情况：队列研究的协作分析。
Lancet HIV. 2017 Aug;4(8):e349-e356. doi: 10.1016/S2352-3018(17)30066-8. Epub 2017 May 10.
8
HIV infection as vascular risk: A systematic review of the literature and meta-analysis.人类免疫缺陷病毒感染作为血管风险：文献系统综述与荟萃分析
PLoS One. 2017 May 11;12(5):e0176686. doi: 10.1371/journal.pone.0176686. eCollection 2017.
9
Interrupting antiretroviral treatment in HIV cure research: scientific and ethical considerations.艾滋病治愈研究中抗逆转录病毒治疗的中断：科学与伦理考量
J Virus Erad. 2017 Apr 1;3(2):82-84. doi: 10.1016/S2055-6640(20)30287-9.
10
Kidney Disease and HIV Infection.肾脏疾病与HIV感染
Top Antivir Med. 2017 Feb/Mar;25(1):13-16.
Zotero 插件